Most recent update: Sunday, April 29, 2018 - 14:56

You are here

thrombosis

Treating thrombo-vascular complications in kidney disease

Researchers at Boston University School of Medicine (BUSM) have discovered a potential treatment target to prevent chronic kidney disease patients from developing thrombosis without causing bleeding complications - an unwanted and perplexing side effect. They say the strategy offers a much-needed therapeutic alternative to standard-of-care heparin, which throws off the finely-tuned balance between pro-clotting and anticoagulant factors in blood vessels that work to keep fluid flowing while protecting against excessive bleeding after injuries.

andexanet stops dangerous bleeding factor Xa inhibitors patients

The experimental drug andexanet was associated with control of serious bleeding in patients taking a common class of anticoagulants known as Factor Xa inhibitors, according to interim clinical trial results presented at the American College of Cardiology's 67th Annual Scientific Session. Millions of patients take Factor Xa inhibitors, which elevate the risk of serious bleeding.

Subscribe to RSS - thrombosis